Showing results (181-190 of 243) with videos related to
Sort By:
Pageof 25
Neuro-Oncology|March 22, 2008
Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomasKathleen R Lamborn, W K Alfred Yung, Susan M Chang, et al.Cancer|March 11, 2020
NRG/RTOG 1122: A phase 2, double-blinded, placebo-controlled study of bevacizumab with and without trebananib in patients with recurrent glioblastoma or gliosarcomaEudocia Q Lee, Peixin Zhang, Patrick Y Wen, et al.Acta Neuropathologica|October 7, 2020
Epigenomic, genomic, and transcriptomic landscape of schwannomatosisSheila Mansouri, Suganth Suppiah, Yasin Mamatjan, et al.Journal of Neuro-Oncology|July 6, 2019
Epidermal growth factor receptor (EGFR) amplification rates observed in screening patients for randomized trials in glioblastomaAndrew B Lassman, Kenneth D Aldape, Peter J Ansell, et al.Nature Communications|May 10, 2023
Multiplatform molecular profiling uncovers two subgroups of malignant peripheral nerve sheath tumors with distinct therapeutic vulnerabilitiesSuganth Suppiah, Sheila Mansouri, Yasin Mamatjan, et al.Neuro-Oncology|January 29, 2014
Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02Patrick Y Wen, Susan M Chang, Kathleen R Lamborn, et al.Cell Genomics|May 24, 2024
Meningioma transcriptomic landscape demonstrates novel subtypes with regional associated biology and patient outcomeH Nayanga Thirimanne, Damian Almiron-Bonnin, Nicholas Nuechterlein, et al.Cancers|November 13, 2021
Identification of MicroRNA-mRNA Networks in Melanoma and Their Association with PD-1 Checkpoint Blockade OutcomesRobert A Szczepaniak Sloane, Michael G White, Russell G Witt, et al.Cell Reports|July 21, 2021
Reprogramming of bivalent chromatin states in NRAS mutant melanoma suggests PRC2 inhibition as a therapeutic strategyChristopher J Terranova, Ming Tang, Mayinuer Maitituoheti, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 13, 2018
Phase I Study of DNX-2401 (Delta-24-RGD) Oncolytic Adenovirus: Replication and Immunotherapeutic Effects in Recurrent Malignant GliomaFrederick F Lang, Charles Conrad, Candelaria Gomez-Manzano, et al.Pageof 25